Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796078 | 1.00 | ALOX5 (0.39) | ALOX5KMT2ASMN1; SMN2MMP9MMP14 | |
| SCHEMBL17796119 | 1.00 | ALOX5 (0.39) | ALOX5KMT2ASMN1; SMN2MMP9MMP14 | |
| SCHEMBL17796076 | 0.83 | KMT2A (0.43) | ALOX5KMT2ASMN1; SMN2L3MBTL1TACR1 | |
| SCHEMBL17796117 | 0.83 | KMT2A (0.43) | ALOX5KMT2ASMN1; SMN2L3MBTL1TACR1 | |
| SCHEMBL17796074 | 0.83 | KMT2A (0.43) | ALOX5KMT2ASMN1; SMN2L3MBTL1TACR1 | |
| SCHEMBL17805702 | 0.83 | LTB4R (0.39) | ALOX5L3MBTL1 | |
| SCHEMBL17831481 | 0.83 | LTB4R (0.39) | ALOX5L3MBTL1 | |
| SCHEMBL17805528 | 0.83 | LTB4R (0.39) | ALOX5L3MBTL1 | |
| SCHEMBL17828391 | 0.81 | L3MBTL1 (0.43) | KMT2APTGS1L3MBTL1CNR1MEN1 | |
| SCHEMBL17828385 | 0.81 | L3MBTL1 (0.43) | KMT2APTGS1L3MBTL1CNR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029043-B1 | TRICYCLIC BENZOXABOROLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | DONG A ST CO LTD (KR) | 2018-08-29 | — | — | EP | disclosed |
| US-9676796-B2 | Tricyclic benzoxaborole compound, preparation method and use thereof | DONG-A ST CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9676796-B2 | Tricyclic benzoxaborole compound, preparation method and use thereof | DONG-A ST CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-20160168167-A1 | Tricyclic Benzoxaborole Compound, Preparation Method and Use Thereof | DONG-A ST CO., LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3029043-A1 | TRICYCLIC BENZOXABOROLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Dong-A ST Co., Ltd. (KR) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168167-A1 | Tricyclic Benzoxaborole Compound, Preparation Method and Use Thereof | CYP2C19, CYP2C9, TBCB | ALOX5 1180/4885KMT2A 3600/4885SMN1; SMN2 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.